Abionyx Pharma (XPAR:ABNX) ROE % Adjusted to Book Value : -7.62% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma ROE % Adjusted to Book Value?

Abionyx Pharma's ROE % for the quarter that ended in Dec. 2023 was -39.95%. Abionyx Pharma's PB Ratio for the quarter that ended in Dec. 2023 was 5.24. Abionyx Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -7.62%.

Abionyx Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Abionyx Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma ROE % Adjusted to Book Value Chart

Abionyx Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

32.01

-7.79

-10.60

-6.98

-8.90

Abionyx Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-14.00	-11.38	-6.21	-10.28	-7.62

Competitive Comparison of Abionyx Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Abionyx Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abionyx Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's ROE % Adjusted to Book Value falls into.

Abionyx Pharma ROE % Adjusted to Book Value Calculation

Abionyx Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-46.62%	/	5.24
	=	-8.90%

Abionyx Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-39.95%	/	5.24
	=	-7.62%

Abionyx Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma (XPAR:ABNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

609:Germany

Address

33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website

https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines